Universal flu vaccine begins testing in the US

On Wednesday, 29th, the National Institutes of Health’s Clinical Center in Bethesda, Maryland (United States) began. first phase of a new clinical trial universal vaccine Against fluthe one which… It was developed by researchers from the US National Institute of Allergy and Infectious Diseases (NIAID)..

The BPL-1357 vaccine and a placebo vaccine will be administered to 100 healthy adult volunteers aged 18 to 55 years. According to NIAID, BPL-1357 was developed with four non-infectious avian influenza viruses It has low pathogenicity and is chemically inactivated.

According to an animal study, Two doses of BPL-1357 vaccine were administered intramuscularly or intranasally in mice. and then, all survived exposure to lethal doses of six different strains of the influenza virus – including non-vaccine strains.

“Influenza vaccines that can provide lasting protection against a wide variety of seasonal flu viruses, as well as those with pandemic potential, will be invaluable public health tools,” said Anthony S. Fauci, MD, Director of NIAID.

Universal flu vaccine

According to the NIAD, the first phase of the study will be conducted with volunteers randomly divided into three groups and Two doses of vaccine or two doses of placebo in 28 days — as in mice, participants will be given intramuscular or intranasal saline solution. The first group will receive the placebo nasally and the vaccine intramuscularly, the second group will receive the reverse, and the third will receive the placebo by both methods.

The study will run for approximately seven months and therefore volunteers must return each month to provide blood and nasal mucosa samples. Also, participants cannot have received any other type of flu vaccine in the last two months before the start of the first phase.